In summary, glial NRG1-I/ErbB2-mediated paracrine and autocrine stimulation represents a novel neurological disease mechanism that constitutes an attractive target for therapeutic approaches of demyelinating peripheral nerve diseases. This evidence concerns the gene ERBB2 and peripheral nervous system disorder.